THE FOLLOWING DEFICIENCY REPRESENTS AN INCIDENT OF PAST NONCOMPLIANCE THAT WAS SUBSEQUENTLY CORRECTED PRIOR TO THIS SURVEY.
Based on staff interview, record review, and website review, the facility failed to provide pharmaceuticals services that assure the accurate acquiring, receiving, and dispensing of drugs when they allowed a company who was not licensed in Ohio by the State Pharmacy Board to administer dangerous Intravenous (IV) fluid medications. This affected three (Residents #42, #43, and #46) of three reviewed for pharmacy services. The facility identified 36 (Residents #9, #10, #11, #15, #18, #20, #21, #23, #25, #26, #27, #28, #33, #34, #39, #41, #42, #43, #46, #48, #51, #52, #53, #59, #60, #61, #62, #63, #64, #65, #66, #67, #68, #69, #70, #71 ) who received IV fluids through the company. The facility census was 56.
Findings include:
1. Record review of Resident #42 revealed an admission date of 06/13/22 with pertinent diagnoses of congestive heart failure, chronic pain syndrome, type one diabetes mellitus with diabetic neuropathy, xerosis cutis, chronic venous hypertension, localized edema, mild intellectual disabilities, anxiety disorder, cellulitis of left lower limb, cognitive communication deficit, morbid obesity, anemia, atherosclerotic heart disease of native coronary, cardiac arrhythmia, heart failure, hyperlipidemia, hypertension, presence of prosthetic heart valve, and peripheral venous insufficiency.
Review of the 07/21/23 quarterly Minimum Data Set (MDS) assessment revealed the resident was cognitively intact and required extensive assistance for bed mobility, transfer, walk in room, walk in corridor, dressing, toilet use, personal hygiene.
Review of a physician order dated 03/13/23 revealed infection and derma infusion protocol-for Agency #700 IV therapy infusion-one time 1000 milliliters (ml) 0.9% normal saline at 1000 ml per (/) hour (hr) additive formula: ascorbic acid 5 gram (gm) b complex - b5 250 milligrams (mg), b7 biotin, 20 mg zinc 10 mg amino blend, glutamine 150 mg, arginine 500 mg, ornithine 150 mg, lysine 250 mg, citrulline 250 mg, and glutathione 600 mg.
Review of a physician order dated 04/13/23 revealed infection and derma infusion protocol-for Agency #700 IV therapy infusion-one time 1000 ml 0.9% normal saline at 1000 ml/hr additive formula: ascorbic acid 5 gm b complex - b5 250 mg, b7 biotin, 20 mg zinc 10 mg amino blend, glutamine 150 mg, arginine 500 mg, ornithine 150 mg, lysine 250 mg, citrulline 250 mg, and glutathione 600 mg.
2. Record review of Resident #43 revealed an admission date of 11/21/22 with pertinent diagnoses of: parapelegia, radiculopathy cervical and thoracic region, muscle wasting and atrophy, colostomy status, morbid obesity, nutritional deficiency, xerosis cutis, neurogenic bladder, acute ischemic heart disease, type two diabetes mellitus, pressure ulcer of sacral region, atrial fibrillation, spinalfusion thoracic and lumbar region, hyperlipidemia, sleep apnea, hypertension, calculus of kidney, and retention of urine.
Review of the 07/20/23 quarterly MDS assessment revealed the resident was totally dependent for transfers and required extensive assistance for bed mobility, dressing, toilet use and personal hygiene.
Review of physician orders dated 03/13/23, 04/11/23, 05/15/23, 06/22/23, 07/20/23, and 08/29/23 revealed infection and derma infusion protocol-for Agency #700 IV therapy infusion-one time 1000 ml 0.9% normal saline at 1000 ml/hr additive formula: ascorbic acid 5 gm b complex - b5 250 mg, b7 biotin, 20 mg zinc 10 mg amino blend, glutamine 150 mg, arginine 500 mg, ornithine 150 mg, lysine 250 mg, citrulline 250 mg, and glutathione 600 mg.
3. Record review of Resident #46 revealed an admission date of 01/27/22 with pertinent diagnoses of: chronic obstructive pulmonary disease, bain disorder, severe protein calorie malnutrition, chronic kidney disease, history of covid-19, chronic respiratory failure with hypoxia, dysphagia, benign neoplasm of cerebral meninges, hyperglycemia, gastro-esophagael reflux disease, arthropathy, history of falling, hyperlipidemia, hypertension, myoneural disorder, iron deficiency anemia, congestive heart failure, edema, vitamin D deficiency, long term opiate use, chronic pain, major depressive disorder, hypertensive heart and chronic kidney disease, and insomnia.
Review of the 10/26/23 annual Minimum Data Set (MDS) assessment revealed the resident was cognitively intact and used a wheelchair to aid in mobility. The Resident was dependent for toileting, chair to chair transfer, and tub or shower transfer. The resident was always incontinent of bowel and bladder.
Review of physician orders dated 03/13/23 and 04/13/23 revealed an order for infection infusion protocol-for Agency #700 IV therapy infusion-one time- 0.9% normal saline at 1000 ml/hr (total additive volume, 22 ml) additive formula: ascorbic acid 5 gm b complex - b5, 250 mg zinc, 10 mg amino blend, glutamine 150 mg, arginine 500 mg, ornithine 150 mg, lysine 250 mg, citrulline 250 mg, glutathione 600 mg.
Review of the Ohio State Pharmacy Board website revealed Agency #700 does not have a valid license to dispense dangerous drugs in Ohio.
Interview with Regional Nurse #300 on 12/05/23 at 2:20 P.M. revealed she found out from their corporate company the facility was going to utilize services from Agency #700 to try to enhance quality of life for residents with weight loss, wounds, or hydration issues. There were different types of nutritional IV bags for skin and hydration. Facility nurses got with the facility Physician and the Physician wrote an order for Agency #700's IV bags. Agency #700's nurse would come in and administer the IV fluids, which consisted of vitamins, supplements, and hydration. The last infusion month was September and Regional Nurse #300 was not sure why the corporate office stopped services, and reported services were on a trial basis.
Interview with Regional Nurse #300 on 12/05/23 at 2:20 P.M. verified Agency #700 did not have an Ohio State Pharmacy Board license to dispense dangerous drugs in Ohio and that the facility was unaware of that at the time of IV administrations from March 2023 to September 2023.
As a result of the incident, the facility took the following corrective actions to correct the deficient practice by 11/29/23:
On 09/22/23, Agency #700 cessation was effective.
On 11/20/23, education was provided to the governing body, Vice President of Operations #305,
and Director of Operations #310 to ensure TDD licensure for Ohio is effective before accepting medication into facility/administration of medication.
Starting on 11/22/23 monitoring of ongoing compliance would take place. The facility will complete audits of any company providing any pharmacy services to ensure that the appropriate TDD licensure is effective in the State of Ohio. Audits will be completed weekly for one month and then monthly times three months. Audits will be taken to the QAPI review.
On 11/29/23, residents who received Agency #700's IV fluids were assessed and had no signs or symptoms or adverse effects related to the IV medications.
On 11/29/23, all contracts that involve providing medications were reviewed to ensure the proper TDD licensure is in place and no issues were found.
On 12/08/23 at 11:16 A.M. an interview with Vice President of Operations #305 confirmed education in regards to proper pharmacy licensure for companies administering medications was provided.
Review of Residents #42, #43, and #46 revealed assessments were completed as indicated in the plan of correction.
This deficiency represents non-compliance investigated under Complaint Number OH00146750.